Clik here to view.
IAS 2017: Glecaprevir/ Pibrentasvir Effective for People with HIV/HCV...
AbbVie's new 8-week pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C coinfection in the EXPEDITION-2 study, according to a presentation...
View ArticleClik here to view.
New Hepatitis C Drugs Reduce Mortality Risk in First 18 Months After Treatment
For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality among people with hepatitis C virus (HCV) infection, according to...
View ArticleClik here to view.
Experts Question Cochrane Review of Hepatitis C DAA Treatment
A systematic review of hepatitis C direct-acting antiviral (DAA) studies published by the Cochrane Collaboration has been strongly criticized by doctors and advocates for its conclusion that there is...
View ArticleClik here to view.
IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices,...
HIV, hepatitis B and C, and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College London reported at the 9th...
View ArticleClik here to view.
Janssen Discontinues Hepatitis C Drug Development Program
Janssen Sciences announced last week that it will stop further development of its experimental hepatitis regimen containing AL-335, odalasvir, and simeprevir, as the market is saturated with effective...
View ArticleClik here to view.
Merck Discontinues Development of Experimental Hepatitis C Drugs
Late last month Merck announced that it was halting further development of 2 investigational hepatitis C therapies. The first is a 3-drug coformulation containing the HCV protease inhibitor...
View ArticleClik here to view.
AASLD 2017: Mavyret Shows High Cure Rates for HCV Genotype 3 and Cirrhosis
Glecaprevir and pibrentasvir, the 2 drugs in the recently approved Mavyret coformulation, demonstrated high sustained response rates for chronic hepatitis C patients with HCV genotype 3 and for people...
View ArticleClik here to view.
AASLD 2017: Curing Hepatitis C Leads to Improved Quality of Life
People who were cured of hepatitis C with direct-acting antivirals had sustained improvements in their health-related quality of life, including both physical and mental health measures, according to...
View ArticleClik here to view.
Coverage of the 2017 AASLD Liver Meeting
HIVandHepatitis.com coverage of the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Washington, DC, October 20-24, 2017. Conference highlights include direct-acting...
View ArticleClik here to view.
AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV
An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to sustained response in all HIV-positive with genotype 1 or 4 acute hepatitis C virus (HCV) infection in the SWIFT-C study, according to a...
View ArticleClik here to view.
AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV
An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to sustained response in all HIV-positive with genotype 1 or 4 acute hepatitis C virus (HCV) infection in the SWIFT-C study, according to a...
View ArticleClik here to view.
AASLD 2017: More Work and Lower Drug Prices Needed to Eliminate Hepatitis C...
Eliminating hepatitis C virus (HCV) as a global public health concern is feasible, but to do so more people need to be tested and treated, and prices of direct-acting antivirals need to come down,...
View ArticleClik here to view.
AASLD 2017: Model Shows Hepatitis C Treatment is Cost-Effective in Japan
Treatment of chronic hepatitis C with direct-acting antivirals can lead to substantial savings by preventing the development of liver failure and liver cancer, according to a mathematical modeling...
View ArticleCoverage of IDWeek 2017
HIVandHepatitis.com coverage of IDWeek 2017, held October 4-8, 2017, in San Diego. Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV Single-Tablet Protease Inhibitor Regimen...
View Article